ES2124852T3 - Formulaciones de rapamicina para administracion oral. - Google Patents

Formulaciones de rapamicina para administracion oral.

Info

Publication number
ES2124852T3
ES2124852T3 ES94307117T ES94307117T ES2124852T3 ES 2124852 T3 ES2124852 T3 ES 2124852T3 ES 94307117 T ES94307117 T ES 94307117T ES 94307117 T ES94307117 T ES 94307117T ES 2124852 T3 ES2124852 T3 ES 2124852T3
Authority
ES
Spain
Prior art keywords
approximately
rapamicine
formulations
oral administration
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94307117T
Other languages
English (en)
Inventor
Robert Paul Waranis
Thomas Waymond Leonard
Maureen Murphy Harrison
Christian Luther Ofslager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2124852T3 publication Critical patent/ES2124852T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS FORMULACIONES DE RAPAMICINA ORALES QUE CONTIENEN DE 0,01 GRAMOS APROXIMADAMENTE A 10,00 GRAMOS APROXIMADAMENTE DE RAPAMICINA POR CADA 100 ML DE LA FORMULACION Y UN SISTEMA SOLVENTE QUE CONTIENE DE UN 0,1 APROXIMADAMENTE A UN 10% APROXIMADAMENTE EN VOLUMEN DE SURFACTANTE, DE UN 0 APROXIMADAMENTE A UN 25% APROXIMADAMENTE EN VOLUMEN DE SOLVENTE INERTE Y DE UN 65 APROXIMADAMENTE A UN 99,95% APROXIMADAMENTE EN VOLUMEN DE UNA SOLUCION DE LECITINA O FOSFOLIPIDA.
ES94307117T 1993-09-30 1994-09-29 Formulaciones de rapamicina para administracion oral. Expired - Lifetime ES2124852T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12952393A 1993-09-30 1993-09-30
US12952993A 1993-09-30 1993-09-30

Publications (1)

Publication Number Publication Date
ES2124852T3 true ES2124852T3 (es) 1999-02-16

Family

ID=26827648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94307117T Expired - Lifetime ES2124852T3 (es) 1993-09-30 1994-09-29 Formulaciones de rapamicina para administracion oral.

Country Status (12)

Country Link
EP (1) EP0648494B1 (es)
AT (1) ATE173628T1 (es)
AU (1) AU688782B2 (es)
DE (2) DE69414810T2 (es)
DK (1) DK0648494T3 (es)
ES (1) ES2124852T3 (es)
FI (1) FI115033B (es)
GR (1) GR3029439T3 (es)
HU (1) HU220870B1 (es)
LU (1) LU90832I2 (es)
NL (1) NL300055I2 (es)
SG (1) SG47803A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4336434A1 (de) * 1993-10-26 1995-04-27 Hoechst Ag Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
PE52896A1 (es) * 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
AU773618B2 (en) * 1998-12-22 2004-05-27 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-insoluble drug delivery system
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
WO2005110360A2 (en) * 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
KR20160120739A (ko) * 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
DK3125875T3 (da) 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
GR3029439T3 (en) 1999-05-28
SG47803A1 (en) 1998-04-17
DE10199046I1 (de) 2002-01-10
EP0648494A1 (en) 1995-04-19
LU90832I2 (fr) 2001-11-12
ATE173628T1 (de) 1998-12-15
HU220870B1 (en) 2002-06-29
NL300055I1 (nl) 2001-12-01
NL300055I2 (nl) 2002-04-02
DE69414810D1 (de) 1999-01-07
DK0648494T3 (da) 1999-08-09
AU7420594A (en) 1995-04-13
HK1010342A1 (en) 1999-06-17
HUT71115A (en) 1995-11-28
AU688782B2 (en) 1998-03-19
FI944535L (fi) 1995-03-31
DE69414810T2 (de) 1999-04-22
HU9402786D0 (en) 1994-12-28
EP0648494B1 (en) 1998-11-25
FI944535A0 (fi) 1994-09-29
FI115033B (fi) 2005-02-28

Similar Documents

Publication Publication Date Title
ES2124852T3 (es) Formulaciones de rapamicina para administracion oral.
CO5011119A1 (es) Jarabe antihistaminico estabilizado
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
DK0948965T3 (da) Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater
EP0221732A3 (en) Sustained release tablets
ES2169105T3 (es) Agentes antitromboticos tripeptidicos.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
ATE163540T1 (de) Retinoid enthaltende, wässrige, gelartige darreichungsform
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
EP0222614A3 (en) Orally administerable sustained release pharmaceutical formulations
ES2169262T3 (es) Composiciones oftalmicas que contienen ciclodextrinas y compuestos de amonio cuaternario.
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
DE59811768D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und modifizierte hämoglobine
DK0656780T3 (da) Lægemidler, der indeholder diphosphonsyrer og salte deraf.
ES2033379T3 (es) Soluciones acuosas de clorhidrato de doxorubicina.
HUP0102075A2 (hu) Stabil mitoxantron-oldatok, eljárás az előállításukra
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
ES2129392T3 (es) Derivados de di-lisogangliosidos.
ES2032572T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para aplicacion topica sobre la piel.
MX9301962A (es) Compuestos heterociclicos.
ES2051643B1 (es) Formulaciones orales de ubidecarenona en forma de soluciones acuosas.
TH61593B (th) สารผสมที่มีเตตราไฮโดรลิพสตาติน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 648494

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: PRODUCT NAME: SIROLIMUS (RAPAMUNE), REGISTRY NO/DATE: EU/1/01/171/001-005 20010313, FIRST REGISTRY NO/DATE: CH55243. 01 20000926

Spc suppl protection certif: C200100027

Filing date: 20010912